- |||||||||| Review, Journal: Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions. (Pubmed Central) - Mar 29, 2024
The glucagon-like-peptide 1 receptor agonists (GLP-1 RA) liraglutide and semaglutide have US FDA approval for the treatment of obesity, and the application for an obesity indication for the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide is presently under FDA review...Ongoing CV outcome trials of oral semaglutide and once weekly injectable tirzepatide will help to establish the role of these therapies among persons with other CV conditions...The impact of pharmacologic-induced weight loss on CV conditions for persons with obesity and established CV conditions is currently under investigation for multiple agents. These therapies may offer new avenues to manage CV risk in persons with obesity and with established or at high risk for CV disease.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on "time in range" in patients with type 2 diabetes. (Pubmed Central) - Mar 22, 2024 These real-world findings indicate that GLP-1RA-based treatment strategies could be superior to oral treatment strategies for improving TIR among patients with T2DM and that once-weekly GLP-1RA may be more effective than a once-daily GLP-1RA. Clinical trial registration: http://www.chinadrugtrials.org.cn/index.html, identifier number ChiCTR2300073697.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date: Effects of Semaglutide in HIV-Associated Lipohypertrophy (clinicaltrials.gov) - Mar 21, 2024 P2, N=108, Active, not recruiting, Not yet recruiting --> Recruiting Trial completion date: Mar 2024 --> Mar 2025
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
CASE SERIES: USE OF GLP-1 RECEPTOR AGONIST IN TYPE 1 DIABETES AND SECONDARY DIABETES () - Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_928; Semaglutide may exert significant metabolic benefits in patients with established T1DM and secondary diabetes. There is need for a dedicated trial examining potential benefits of semaglutide in T1DM and patients who develop diabetes after partial pancreatectomy.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trends in GLP-1 Use in US Adolescents and Young Adults (Convention Center Exhibit Hall) - Mar 16, 2024 - Abstract #PAS2024PAS_2443; This rise was most pronounced in females, for whom this number reached 4,698 and 4,446 patients, respectively, in Q2 2023 (Fig. 1a).
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
DELAYED GASTRIC EMPTYING AS A CONSEQUENCE OF PATIENTS ON NEW-GENERATION GLP1-RAS: AN ANALYSIS FROM THE FAERS DATABASE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1370; Of these events, 15,399 (55.3%) were gastrointestinal (GI) issues and of these GI issues, delayed gastric emptying accounted for 2437 (15.8%) events. Of the 2437 that delayed gastric emptying, 151 (6.2%) involved an intestinal obstruction.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
How Well Can Insurers Police Off-Label Use? Evidence from GLP-1s in Medicare Part D () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1717; Our results present early evidence that there is some off-label use of Ozempic in the Medicare program. However, important caveats about the ability of claims data to examine off-label use, including the comprehensiveness and fidelity of diagnosis codes apply.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
The Effect of Approved Anti-Obesity Medications in Patients With Alcohol and Substance Abuse Disorder () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1672; Patients in the AOM cohort had at least one pharmacy claim for Ozempic, Wegovy, or Mounjaro during the identification period (January 1, 2021-August 31, 2022), and one claim for obesity in the baseline. Given that the AOM cohort had a significantly lower incidence of SUD and AUD outcomes than the non-AOM cohort, AOMs may be effective in reducing SUD and AUD events among patients with obesity.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
The Effect of Newly Approved Obesity Medications on Cardiovascular Complications () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1539; This study analyzed the impact of approved obesity medications, such as Ozempic, Wegovy, and Mounjaro, on CVD. Our results suggest that the utilization of AOMs effectively alleviates the high prevalence of CVD and its social and economic costs.
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Safety Profile of Semaglutide in People Aged 55 Years and Over: Pooled Data from the PIONEER, SUSTAIN, and STEP Phase 3 Clinical Programmes (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_4436; P3 Semaglutide 2.4mg therapy was predicted to be cost-effective at a $150,000 WTP threshold. Objective:We investigated the safety of semaglutide in people with T2D and/or overweight/obesity ?55 years from the phase 3a PIONEER, SUSTAIN and STEP clinical programmes.Background:The glucagon-like peptide-1 analogue semaglutide, approved for type 2 diabetes (T2D) and overweight/obesity, is being investigated in the phase 3 evoke and evoke+ trials in people with early AD aged 55
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
THE USE OF SEMAGLUTIDE IN PATIENT WITH PRADER?WILLI SYNDROME: A CASE REPORT () - Mar 6, 2024 - Abstract #ATTD2024ATTD_1104; GLP?1 receptor agonists such as exenatide and liraglutide have been used in the management of diabetes in patient with PWS however, there is limited data on the usage of semaglutide. This case study suggests that the semaglutide may have the potential of improving glycaemic control and achieve weight loss in patients in PWS.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Trial initiation date: Subcutaneous Semaglutide in Systemic Scleroderma (clinicaltrials.gov) - Mar 5, 2024 P1, N=10, Recruiting, This case study suggests that the semaglutide may have the potential of improving glycaemic control and achieve weight loss in patients in PWS. Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Feb 2024
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial initiation date, Trial primary completion date: SEMASEARCH, Retrospective/Prospective Cohort Nested at ATUc/AP2 WEGOVY (clinicaltrials.gov) - Mar 2, 2024 P=N/A, N=1000, Not yet recruiting, Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Feb 2024 Trial completion date: Sep 2025 --> Apr 2026 | Initiation date: Sep 2023 --> Apr 2024 | Trial primary completion date: Sep 2025 --> Apr 2026
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Trial completion: OTID: Obesity Treatment to Improve Diabetes (clinicaltrials.gov) - Feb 28, 2024 P=N/A, N=60, Completed, Not yet recruiting --> Recruiting Recruiting --> Completed
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Efficacy and safety of incretin-based therapy in MASLD patients with type 2 diabetes mellitus (New Hall) - Feb 11, 2024 - Abstract #APASL2024APASL_2942; Background and Aim: The aim of this study was to evaluate the efficacy and safety of oral semaglutide (Sema), a GLP-1 receptor agonist, and tirzepatide (TZP), a dual GIP/GLP-1 receptor agonist, in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) complicated by type 2 diabetes mellitus (T2DM)... Sema and TZP treatments offered a favorable effect on MASLD as well as improving diabetic status and reducing body weight.
|